SPC
ARIA

Slate Path Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Slate Path Capital’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,620,000
Closed -$53.4M – 21
2014
Q1 		$53.4M Buy
+6,620,000
New +$51.6M 4.04% 11

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Slate Path Capital's ARIA Position: Q2 2014 in Review

Slate Path Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2014, closing a stake of 6,620,000 shares — an estimated $53.4M sold.

Slate Path Capital first reported a position in ARIA in Q1 2014 and held it in 1 quarter. The position peaked at $53.4M in Q1 2014. 169 funds tracked by Wall St. Rank hold ARIA as of Q2 2014.

  • Slate Path Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Slate Path Capital sold 6,620,000 Ariad Pharmaceuticals Inc shares in Q2 2014, an estimated $53.4M.
  • Slate Path Capital first reported a position in Ariad Pharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • Slate Path Capital's Ariad Pharmaceuticals Inc position peaked at $53.4M in Q1 2014.
  • 169 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2014.

Based on Slate Path Capital's 13F filing for Q2 2014, filed 14 Aug 2014.